Cabozantinib showed ORR of 16.6% in six patients with ChRCC histology included in a retrospective analysis conducted by Campbell et al. [28] Moreover, the retrospective analysis exploring the efficacy of PD-1 or PDL-1, alone or in combination with anti CTLA-4 in ncRCC, showed no objective response in the 10 patients with chRCC. Here, CTLA4 is linked to chromophobe renal cell carcinoma.